Core Points - Coherus BioSciences, Inc. will release its third quarter 2024 financial results after market close on November 6, 2024 [1] - A conference call and webcast will be hosted by Coherus' management team at 5:00 p.m. ET on the same day to discuss the financial results and provide a business update [1][3] - The press release with the financial results and related materials will be available on the Coherus investor website prior to the conference call [3][4] Conference Call Information - The conference call is scheduled for November 6, 2024, starting at 5:00 p.m. Eastern Time [3] - Participants are required to pre-register to receive dial-in information and a personal PIN for the live call [3] - A live and archived webcast will be accessible on the "Investors" section of the Coherus website [4] Disclosure Information - Coherus utilizes its investor website to disclose material non-public information in compliance with Regulation FD [5] - Contact information for investor relations is provided for further inquiries [5]

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Jami Taylor - Head of Investor Relations Dennis Lanfear - President and Chief Executive Officer Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Rosh Dias - Chief Medical Officer Bryan McMichael - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Chase & Co. Douglas Tsao - H.C. Wainwright & Co. Billal Jahangiri - Truist Securitie ...

Group 1 - Coherus BioSciences reported a quarterly loss of $0.14 per share, better than the Zacks Consensus Estimate of a loss of $0.21, and improved from a loss of $0.38 per share a year ago, representing an earnings surprise of 33.33% [1] - The company posted revenues of $64.98 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 13.85%, compared to year-ago revenues of $58.72 million [2] - Coherus BioSciences shares have declined approximately 62.8% since the beginning of the year, contrasting with the S&P 500's gain of 9% [3] Group 2 - The earnings outlook for Coherus BioSciences is mixed, with the current consensus EPS estimate for the coming quarter at -$0.08 on revenues of $59.86 million, and -$0.63 on revenues of $255.79 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 37% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact Name ...

Exhibit 99.1 Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update – Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI – – Bryan McMichael Appointed as Chief Financial Officer – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., August 8, 2024 -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for ...

"With the divesture of YUSIMRY, Coherus reinforces its strategic focus on oncology," said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "The proceeds from the sale of YUSIMRY will bolster our cash position, advance our efforts to become a sustainable and growing oncology company and efficiently allocate our resources for maximum value creation." About Coherus BioSciences Coherus markets LOQTORZI® (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, and UDENYCA® (pegfilgrastim-cbqv), a ...

"With the divesture of YUSIMRY, Coherus reinforces its strategic focus on oncology," said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "The proceeds from the sale of YUSIMRY will bolster our cash position, advance our efforts to become a sustainable and growing oncology company and efficiently allocate our resources for maximum value creation." Latham & Watkins LLP provided Coherus with legal counsel regarding the transaction. Coherus' immuno-oncology pipeline includes multiple antibody immu ...

REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 1 ...

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained over the dosing interval, establishing proof of mechanism Preclinical data and preliminary clinical results support further evaluation of CHS-114 in combination with the anti-programmed cell death protein 1 (PD-1) antibody, toripalimab-tpzi, and other immuno-onco ...

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus ...